E-viri
Recenzirano
Odprti dostop
-
Advani, Ranjana H.; Li, Hailun; Hoppe, Richard T.; Bartlett, Nancy L.; Bennett, John M.; Neuberg, Donna S.; Cassileth, Peter A; Kahl, Brad S.; Horning, Sandra J.
Blood, 11/2012, Letnik: 120, Številka: 21Journal Article
Abstract 4779 The Stanford V regimen is a combined modality approach for treatment of Hodgkin lymphoma (HL). E1492, an ECOG pilot study, consisted of 12 weeks of Stanford V chemotherapy followed by 36 Gy radiation therapy (RT) to sites > 5 cm or macroscropic splenic disease at diagnosis. Efficacy results were reported previously (Horning et al. J Clin Onc 18, 2000). The study now has a median follow up of 17 years and patients have been followed for overall survival (OS) and development of second cancers. 47 eligible patients with stage bulky mediastinal (mass > one third of the maximum intrathoracic diameter) stage I-II or stage III-IV HL were enrolled between March 1992 and February 1995. Patients were followed every 3 months during the first year off therapy, every 6 months during years 2–5 and annually thereafter. The ECOG database was reviewed for OS and reported second cancers. Patient characteristics at baseline, type of second cancer and time to development of second cancer were assessed. RT summary forms were reviewed for patients with second cancers. 41 patients were treated with combined modality therapy and 6 with chemotherapy alone. The median age was 32 years (range 20–56 years). The 5 and 10 year OS are 96%, and 89% respectively. Seven second cancers were reported, as shown in the Table. The cumulative incidence for second cancers accounting for death as a competing risk is 0.02 (95% CI, 0–0.06) at 5 years, 0.07 (95% CI, 0–0.14) at 10 years, and 0.15 (95% CI, 0.04–0.27) at 15 years. Complete details of the exact location, histologic subtype and subsequent management of second cancers were not available for review. Five of the 7 cancers 2 skin, 1 prostate, 2 acute myeloid leukemia (AML) were not radiation-related. One patient developed AML after primary therapy as reported in the initial publication. A second patient developed AML 5 years after salvage therapy followed by autologous stem cell transplant for relapsed HL. It is likely the 2 cases of breast cancer were treatment related. Within the caveats of a retrospective analysis from a small cooperative group phase 2 trial, the mature 10 year OS of 89% and low frequency of secondary cancers are encouraging in comparison to historic treatment with combined modality treatment. Longer follow up of other Stanford V regimen data sets (i.e. United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 and the Eastern Cooperative Oncology Group E2496) are required to confirm these findings.TablePatientAge (y) at RxAnn Arbor StageTime (y) from study registration to Second CancerType of Second CancerRT FieldCommentTreated with combined modality (n=5)136IX10BreastMantle and left chest wallSite of breast cancer unknown.228IV12Breast (DCIS)Bilateral supraclavicular; mediastinum; bilateral lungsBoth breasts received 15 Gy RT3156III8ProstateUpper para-aortic; right mesentericNo pelvic RT437II9AMLBilateral supraclavicular; mediastinumDeveloped 5 years post ASCT for relapsed HL538III14Skin (face)Bilateral supraclavicular; mediastinum; spleenNo RT to faceTreated with chemotherapy alone (n=2)645IVNASkin (lip)—7243IV1AML—Reported in original publicationAbbreviations: radiation therapy (RT); acute myeloid leukemia (AML); autologous stem cell transplant (ASCT); Not Available (NA); Hodgkin lymphoma (HL); bulky mediastinal disease (X); ductal carcinoma in situ (DCIS).1Note: Patient also diagnosed with renal cancer 1 month before start of RT;2Patient died. No relevant conflicts of interest to declare.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.